NCT Number: NCT05768971
Contrast-enhanced Ultrasound in Patients With Crohn´s Disease and Food Allergy
The purpose of this study is to investigate differences of the bowel wall thickness visible in conventional ultrasound and bowel perfusion using quantitative Contrast-Enhanced Ultrasound in patients with Crohn´s disease in comparison with healthy controls and patients with food allergy.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Observational
About this study
After being informed about the study and potential risks, all participants giving written consent will undergo conventional transabdominal ultrasound and Contrast-Enhanced Ultrasound of the bowel wall with measurement of the bowel wall thickness. In addition a continuous video sequence during Contrast-Enhanced Ultrasound is recorded and perfusion kinetics from the video clips are analyzed using a specific quantification software.
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Age over 18
- Endoscopically and histologically confirmed active Crohn´s disease or
- Previously proven food allergy (double-blind or single-blind food challenge tests with placebo controls previously before the sonographic examination, increased blood and / or intestinal Immunoglobulin E levels, elevated methylhistamine values under provocation and with reproducible reactions during food challenge procedures) or
- Healthy individuals without abdominal complaints
Exclusion criteria
- Age under 18
- Intolerance of the ultrasound contrast agent SonoVue
- Refusal of participation in the study
- Pregnancy or breast-feeding
Treatment and study plan
Provocative diet
OtherPrimary outcomes
-
Bowel wall thickness
Time frame: T0: Baseline after mild diet. T1: After provocative diet (up to 30 days from T0)
Thickness of the bowel wall measured in high-frequency ultrasound from the center of the lumen to the serosa
-
Peak Enhancement
Time frame: T0: Baseline after mild diet. T1: After provocative diet (up to 30 days from T0)
Maximum point of the DCE-US curve assessed in Contrast-Enhanced Ultrasound
Sponsors and collaborators
Lead sponsor
Friedrich-Alexander-Universität Erlangen-Nürnberg
Other
Registry information
Official study title
Conventional Ultrasound and Quantitative Dynamic Contrast-Enhanced Ultrasound (DCE-US) of the Bowel Wall in Patients With Food Allergy in Comparison to Crohn´s Disease and Healthy Controls
Important dates
- Study start
- 2012
- Primary completion
- 2014
- Study completion
- 2014
- First posted
- Mar 15, 2023
- Registry last updated
- Mar 15, 2023
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT04673357
Crohn Disease, Digestive System Diseases
Wilmington, Delaware, United States
View Trial DetailsA Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Participants With Moderately to Severely Active Crohn's Disease (MK-7240-006)
NCT05013905
Crohn Disease, Digestive System Diseases
Los Angeles, California, United States
View Trial DetailsIBD-Sleep: A Pilot Study Looking at Changes in Sleep Timing and IBD Symptoms
NCT06094608
Colitis, Colitis, Ulcerative
Ann Arbor, Michigan, United States
View Trial DetailsLoss of RESponse to Ustekinumab Treated by Dose Escalation
NCT04245215
Crohn Disease, Digestive System Diseases
Zaventem, Belgium
View Trial Details